Aerie Pharmaceuticals — Investor Presentation (January 2019)
25 slides from Aerie Pharmaceuticals's investor presentation, Jan 7, 2019

Slide 1: Company Overview Investor Presentation January 2019
Company Overview Investor Presentation January 2019 Exhibit 99.1

Slide 2: Important Information
Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety

Slide 3: Aerie Overview
Aerie IOP–Reducing Products (IP 2030+) Pipeline Activities Rhopressa® – normal tension glaucoma, pseudo ex glaucoma, corneal healing... Retina Program – AR-13503 and AR-1105 (IND filed Q4 2018) implants Sustained-Release Implant Manufacturing Platform Beyond Ophthalmology – potential for Aerie-owned

Slide 4: Rhopressa®: Market Perspective
Rhopressa®: Market Perspective Refer to the full Rhopressa® product label at www.rhopressa.com For Investor Use - ~$3B Market, 37M TRx, 61M bottles - Half of volume first-line (PGAs) - Half of volume 2-3X/Day Adjuncts - New drug class - Once-daily dosing directed at site of pathology: the trabecular

Slide 5: Rhopressa® Formulary Coverage Increasing
Rhopressa® Formulary Coverage Increasing For Investor Use As of 10/01/18: ~85% of Commercial Lives Covered ~40% Medicare Part D Lives Covered During Q1 2019 Expect Majority Preferred Tier 2 Coverage Commercial and Medicare Part D ------------Commercial------------- -----------Medicare Part D--------

Slide 6: Rhopressa® U.S. Launch Update
Rhopressa® U.S. Launch Update Weekly IQVIA Total Rx’s and Extended Units: For Investor Use Week 37: 12/21/18 *Actual bottles dispensed exceed TRx’s due to extended supply plans (e.g., 90 days’ supply) Rhopressa® has not been approved by any regulatory authority other than the FDA. 7,707 6,034 Week E

Slide 7: Rhopressa® U.S. Launch Update
Rhopressa® U.S. Launch Update For Investor Use Rhopressa® has not been approved by any regulatory authority other than the FDA. Strong Net Sales and Volume Growth: $136 net sales per unit $122 net sales per unit Fully Expect to Meet FY 2018 Net Sales Guidance of $20 to $30 million

Slide 8: Active Engagement at Key Conferences
Active Engagement at Key Conferences American Glaucoma Society (AGS) March 2018 American Society of Cataract and Refractive Surgeons (ASCRS) April 2018 Association of Research in Vision and Ophthalmology (ARVO) April 2018 European Glaucoma Society (EGS) Florence, May 2018 European Society of Catarac

Slide 9: Rocklatan™ Positioning as First Line Therapy
RocklatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Positioning as First Line Therapy: Benefits of Rhopressa® while also targeting the secondary drain Achieved statistical superiority to market-leading latanoprost At each of nine time points in each of the two Phase 3 trials If app

Slide 10: Rocklatan™ Efficacy and Safety
RocklatanTM Efficacy and Safety Efficacy: RocklatanTM demonstrated statistical superiority over its components (market-leading PGA latanoprost and Rhopressa®) in Mercury 1 and 2 Phase 3 trials, at all measured time points Consistent incremental IOP-reduction over latanoprost and Rhopressa® in the ra

Slide 11: Rocklatan™ Responder Analysis
RocklatanTM Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible At Month 12: % of Patients with IOP Reduced to 18 mmHg or Lower *p<0.05, **p<0.01, ***p<0.0001 * ** *** ++Data on File Based on Mercury 1 Interim Analysis 2 For Investor Use

Slide 12: Rocklatan™ Next Steps
Rocklatan™ Next Steps March 14, 2019 PDUFA Current U.S. sales force will be trained on RocklatanTM in advance of PDUFA Medicare Part D formulary submission to payers expected in April 2019 Commercial and Medicare Part D access expected to be accelerated in comparison to Rhopressa® For Investor Use

Slide 13: Expanding Aerie Franchise: Europe and Japan
Expanding Aerie Franchise: Europe and Japan Europe (2017 Europe “Big 5” Glaucoma Market: 91M units per year, 1.5X U.S. units) MAA accepted for Rhokiinsa® (Rhopressa®) in October 2018, expect 12-month review Mercury 3: 6-month safety and 90-day efficacy registration trial comparing RocklatanTM for no

Slide 14: Europe Glaucoma Market
Europe Glaucoma Market: Aerie Expects to Commercialize on Its Own (if approved) “Big 5” Europe Glaucoma Market – 2017 $1.0B; 91M TRx*, Market Share in TRx PGA: Prostaglandin Analogue; BB: Beta Blocker; AA: Alpha Agonist; CAI: Carbonic Anhydrase Inhibitor Sources: IQVIA Analytics Link at ex-manufactu

Slide 15: Japan Glaucoma Market
Japan Glaucoma Market: Aerie Expects to Partner for Commercialization (if approved) PGA: Prostaglandin Analogue; BB: Beta Blocker; AA: Alpha Agonist; CAI: Carbonic Anhydrase Inhibitor Sources: IQVIA Analytics Link at ex-manufacturer price level. *TRx calculated from IQVIA unit data (1 month = 1 TRx)

Slide 16: Advancing the Pipeline
Advancing the Pipeline AR-13503 and AR-1105 are preclinical stage molecules and have not been approved by the FDA or any regulatory agency Additional potential Rhopressa® indications are being considered for further study and are not labeled indications. Rhopressa® Research Targets 24-hour IOP reduc

Slide 17: Retinal Eye Diseases – Aerie's Next Chapter
Retinal Eye Diseases – Aerie’s Next Chapter For Investor Use Bringing Small Molecule Therapy to Back of the Eye Most retinal drugs in use and in pipeline are protein therapeutics Longer half-life allows monthly to bimonthly IVT injections Protein therapeutics address limited number of extracellular

Slide 18: 2017 U.S. Retinal Disease Market
2017 U.S. Retinal Disease Market For Investor Use 2017 Sales: $5.3B Unit Sales: 6.8M Sources: Mix of public information, IQVIA and estimates

Slide 19: Aerie's Innovation in Retinal Disease
Aerie’s Innovation in Retinal Disease For Investor Use Small Molecule Drug Candidates Proprietary Drug Delivery Technology Bio-erodible, sustained-release implant for intravitreal injection DSM PEA Polymer PLGA PRINT® Mfg Aerie Kinase Library Non-Aerie drug candidates AMD DME RVO Dry AMD/GA Glaucoma

Slide 20: Retinal Eye Disease Unmet Needs in AMD and DME
Retinal Eye Disease For Investor Use Unmet Needs in AMD and DME Need new treatments to address disease mechanisms beyond VEGF Complex pathology cannot be addressed by a single drug class Many patients do not achieve and/or maintain sufficient efficacy AMD: Anti-VEGF efficacy often lost after 5–7 yea

Slide 21: Lead Retina Products
Lead Retina Products For Investor Use AR-1105 (Dexamethasone) Implant Indications: retinal vein occlusion (RVO) and DME Target product profile vs. Ozurdex® Longer duration of efficacy (6 mo vs 3 mo) Improved administration due to smaller needle Potential for fewer adverse effects due to lower peak d

Slide 22: AR-13503 Provides Efficacy Similar to Eylea® in PDR Model
Oxygen-induced retinopathy (OIR) mouse model - PDR Administration: Intraperitoneal QD For Investor Use Preclinical AR-13503 Provides Efficacy Similar to Eylea® in a Proliferative Diabetic Retinopathy Model Vehicle (n=14) 1.25 mg/kg AR-13503 (n=16) 1 mg/kg Eylea (n=14) Data on File For more informati

Slide 23: AR-13503 Synergistic to Eylea® in Mouse Model
AR-13503 Synergistic to Eylea® in Mouse Model of Proliferative Diabetic Retinopathy Oxygen-induced retinopathy (OIR) mouse model - PDR -40% *** * Administration: Intraperitoneal QD * : p<0.01 *** : p<0.0001 For Investor Use -60% % of Total Area Neovascular Area (+SEM) Data on File Sub-optimal dose l

Slide 24: Evaluating Aerie's 3,500+ Owned Molecules
Evaluating Aerie’s 3,500+ Owned Molecules ROCK Commencing screening for additional indications beyond ophthalmology ROCK inhibition should have potential in: Pulmonary health, including pulmonary fibrosis and bronchial asthma Dermatology indications Cancer Others Relationship tree of human kinases.

Slide 25: Summary Key Priorities
Summary Key Priorities Rhopressa®: Continued successful launch execution RocklatanTM: U.S. PDUFA set for March 14, 2019 Globalization Strategy Europe/Japan clinical path and commercialization strategy Ireland Manufacturing Facility Research Initiatives Rhopressa® 24-hour IOP reduction, normal tensio
Source: SEC EDGAR · 8-K filed Jan 7, 2019
More decks from Aerie Pharmaceuticals Inc.
Investor Presentation (September 2022)30 slides · Sep 13, 2022
Merger or Acquisition (August 2022)30 slides · Aug 23, 2022
Investor Presentation (June 2022)30 slides · Jun 8, 2022
Investor Presentation (May 2022)28 slides · May 25, 2022
Investor Presentation (April 2022)25 slides · Apr 11, 2022
Investor Presentation (January 2022)33 slides · Jan 5, 2022